| 1 |
Adams A, Gupta V, Mohsen W, Chapman TP, Subhaharan D, Kakkadasam Ramaswamy P, Kumar S, Kedia S, McGregor CG, Ambrose T, George BD, Palmer R, Brain O, Walsh A, Ahuja V, Travis SPL, Satsangi J. Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response. Gut 2023;72:433-42. [PMID: 36171080 DOI: 10.1136/gutjnl-2022-327533] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 2 |
Khor TS, Claudtiz TS, Kővári B, Lauwers GY, Wallace MB, Kumarasinghe P. Inflammatory Conditions of the Colon. Gastrointestinal Pathology 2021. [DOI: 10.1002/9781119073048.ch10] [Reference Citation Analysis]
|
| 3 |
Damião AOMC, Azevedo MFC, Carlos AS, Wada MY, Silva TVM, Feitosa FC. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review. World J Gastroenterol 2019; 25(9): 1142-1157 [PMID: 30863001 DOI: 10.3748/wjg.v25.i9.1142] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 47] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 4 |
Jairath V, Mcdonald JW, Feagan BG. Ulcerative Colitis. Evidence-based Gastroenterology and Hepatology 4e 2019. [DOI: 10.1002/9781119211419.ch11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 5 |
Saniabadi AR, Tanaka T, Yamamoto T, Kruis W, Sacco R. Granulomonocytapheresis as a cell-dependent treatment option for patients with inflammatory bowel disease: Concepts and clinical features for better therapeutic outcomes. J Clin Apher. 2019;34:51-60. [PMID: 30407662 DOI: 10.1002/jca.21670] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 6 |
Kho ZY, Lal SK. The Human Gut Microbiome - A Potential Controller of Wellness and Disease. Front Microbiol 2018;9:1835. [PMID: 30154767 DOI: 10.3389/fmicb.2018.01835] [Cited by in Crossref: 451] [Cited by in F6Publishing: 474] [Article Influence: 90.2] [Reference Citation Analysis]
|
| 7 |
Gisbert JP, Chaparro M. Acute severe ulcerative colitis: State of the art treatment. Best Pract Res Clin Gastroenterol 2018;32-33:59-69. [PMID: 30060940 DOI: 10.1016/j.bpg.2018.05.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 8 |
Kanai T. Leukocytapheresis Therapy of Inflammatory Bowel Disease. Crohn's Disease and Ulcerative Colitis 2017. [DOI: 10.1007/978-3-319-33703-6_49] [Reference Citation Analysis]
|
| 9 |
Sacco R, Tanaka T, Yamamoto T, Bresci G, Saniabadi AR. Adacolumn leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders and unresponders. Expert Rev Gastroenterol Hepatol 2015;9:327-33. [PMID: 25160857 DOI: 10.1586/17474124.2014.953060] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 10 |
Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without drugs. World J Gastroenterol 2014; 20(29): 9699-9715 [PMID: 25110409 DOI: 10.3748/wjg.v20.i29.9699] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 11 |
Botta GP, Blonski W, Lichtenstein GR. Cyclosporine for Ulcerative Colitis. Medical Therapy of Ulcerative Colitis 2014. [DOI: 10.1007/978-1-4939-1677-1_13] [Reference Citation Analysis]
|
| 12 |
Miya Y, Goda M, Akiyoshi H, Ohashi F. Constant Rate Infusion of Cyclosporine for Inflammatory Bowel Disease in a dog. J Jpn Vet Med Assoc 2014;67:608-611. [DOI: 10.12935/jvma.67.608] [Reference Citation Analysis]
|
| 13 |
Jain D, Warren BF, Riddell RH. Inflammatory Disorders of the Large Intestine. Morson and Dawson's Gastrointestinal Pathology 2012. [DOI: 10.1002/9781118399668.ch35] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 14 |
C Leitner G, Worel N, Vogelsang H. Selective Granulocyte and Monocyte Apheresis as a Non-Pharmacological Option for Patients with Inflammatory Bowel Disease. Transfus Med Hemother 2012;39:246-52. [PMID: 22969694 DOI: 10.1159/000341801] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 15 |
Beddy D, Dozois EJ, Pemberton JH. Perioperative complications in inflammatory bowel disease. Inflamm Bowel Dis 2011;17:1610-9. [PMID: 21674718 DOI: 10.1002/ibd.21504] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 16 |
Leblanc S, Allez M, Seksik P, Flourié B, Peeters H, Dupas JL, Bouguen G, Peyrin-Biroulet L, Duclos B, Bourreille A, Dewit O, Bouhnik Y, Michetti P, Chaussade S, Saussure P, Mary JY, Colombel JF, Lémann M; GETAID. Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis. Am J Gastroenterol 2011;106:771-7. [PMID: 21386832 DOI: 10.1038/ajg.2011.62] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 17 |
Walch A, Meshkat M, Vogelsang H, Novacek G, Dejaco C, Angelberger S, Mikulits A, Miehsler W, Gangl A, Reinisch W. Long-term outcome in patients with ulcerative colitis treated with intravenous cyclosporine A is determined by previous exposure to thiopurines. J Crohns Colitis 2010;4:398-404. [PMID: 21122535 DOI: 10.1016/j.crohns.2010.01.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 18 |
Jewell DP, Sutherland LR, Mcdonald JW, Feagan BG. Ulcerative Colitis. Evidence‐Based Gastroenterology and Hepatology 2010. [DOI: 10.1002/9781444314403.ch12] [Reference Citation Analysis]
|
| 19 |
Hart AL, Ng SC. Review article: the optimal medical management of acute severe ulcerative colitis. Aliment Pharmacol Ther 2010;32:615-27. [PMID: 20626381 DOI: 10.1111/j.1365-2036.2010.04392.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 20 |
Stewart D, Chao A, Kodner I, Birnbaum E, Fleshman J, Dietz D. Subtotal colectomy for toxic and fulminant colitis in the era of immunosuppressive therapy. Colorectal Dis 2009;11:184-90. [PMID: 18477020 DOI: 10.1111/j.1463-1318.2008.01579.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 21 |
Yamamoto S, Nakase H, Mikami S, Inoue S, Yoshino T, Takeda Y, Kasahara K, Ueno S, Uza N, Kitamura H, Tamaki H, Matsuura M, Inui K, Chiba T. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther 2008;28:589-97. [PMID: 18549460 DOI: 10.1111/j.1365-2036.2008.03764.x] [Cited by in Crossref: 81] [Cited by in F6Publishing: 63] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 22 |
Hanai H. Leucocytapheresis for inflammatory bowel disease in the era of biologic therapy. Eur J Gastroenterol Hepatol 2008;20:596-600. [PMID: 18679059 DOI: 10.1097/MEG.0b013e3282f5e9f3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 23 |
Aceituno M, García-Planella E, Heredia C, Zabana Y, Feu F, Domènech E, Gassull MA, Panés J. Steroid-refractory ulcerative colitis: predictive factors of response to cyclosporine and validation in an independent cohort. Inflamm Bowel Dis 2008;14:347-52. [PMID: 18050296 DOI: 10.1002/ibd.20322] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 24 |
Baudet A, Rahmi G, Bretagne AL, Gloro R, Justum AM, Reimund JM. Severe ulcerative colitis: present medical treatment strategies. Expert Opin Pharmacother. 2008;9:447-457. [PMID: 18220494 DOI: 10.1517/14656566.9.3.447] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 25 |
Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: A review of medical therapy. World J Gastroenterol 2008; 14(3): 354-377 [PMID: 18200659 DOI: 10.3748/wjg.14.354] [Cited by in CrossRef: 154] [Cited by in F6Publishing: 163] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 26 |
ACUTE FULMINATING COLITIS AND EMERGENCY COLECTOMY. Surgery of the Anus, Rectum & Colon 2008. [DOI: 10.1016/b978-0-7020-2723-9.50044-0] [Reference Citation Analysis]
|
| 27 |
Lindsey I, Mortensen NJM. Surgical management of ulcerative colitis. Inflammatory Bowel Disease: From Bench to Bedside. [DOI: 10.1007/0-387-25808-6_31] [Reference Citation Analysis]
|
| 28 |
Sandborn WJ. Medical management of ulcerative colitis. Inflammatory Bowel Disease: From Bench to Bedside. [DOI: 10.1007/0-387-25808-6_30] [Reference Citation Analysis]
|
| 29 |
Carbonnel F. Prise en charge d’une rectocolite hémorragique sévère ou corticorésistante. Gastroentérologie Clinique et Biologique 2007;31:398-403. [DOI: 10.1016/s0399-8320(07)89399-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 30 |
Hanai H. Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol 2006; 12(47): 7568-7577 [PMID: 17171783 DOI: 10.3748/wjg.v12.i47.7568] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 38] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 31 |
Weber A, Fein F, Koch S, Dupont-Gossart AC, Mantion G, Heyd B, Carbonnel F. Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (Neoral). Inflamm Bowel Dis 2006;12:1131-5. [PMID: 17119387 DOI: 10.1097/01.mib.0000235096.78736.8e] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 32 |
Castro M, Papadatou B, Ceriati E, Knafelz D, De Angelis P, Ferretti F, Gambarara M, Diamanti A, De Peppo F, Rivosecchi M. Role of cyclosporin in preventing or delaying colectomy in children with severe ulcerative colitis. Langenbecks Arch Surg 2007;392:161-4. [DOI: 10.1007/s00423-006-0068-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 33 |
Regueiro M, Curtis J, Plevy S. Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol 2006;40:476-81. [PMID: 16825928 DOI: 10.1097/00004836-200607000-00004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 34 |
Creed TJ, Probert CS, Norman MN, Moorghen M, Shepherd NA, Hearing SD, Dayan CM; BASBUC INVESTIGATORS. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment Pharmacol Ther 2006;23:1435-42. [PMID: 16669958 DOI: 10.1111/j.1365-2036.2006.02904.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 35 |
García-López S, Gomollón-García F, Pérez-Gisbert J. Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterol Hepatol. 2005;28:607-614. [PMID: 16373009 DOI: 10.1016/s0210-5705(05)71523-5] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 36 |
Kanai T, Hibi T, Watanabe M. The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease. Expert Opinion on Biological Therapy 2006;6:453-66. [DOI: 10.1517/14712598.6.5.453] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 37 |
Sands BE. Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories? Gut 2006;55:437-41. [PMID: 16531519 DOI: 10.1136/gut.2005.078055] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 38 |
Pham CQ, Efros CB, Berardi RR. Cyclosporine for severe ulcerative colitis. Ann Pharmacother 2006;40:96-101. [PMID: 16368919 DOI: 10.1345/aph.1G374] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 39 |
Durai D, Hawthorne AB. Review article: how and when to use ciclosporin in ulcerative colitis. Aliment Pharmacol Ther 2005;22:907-16. [PMID: 16268964 DOI: 10.1111/j.1365-2036.2005.02680.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 40 |
Kugathasan S, Dubinsky MC, Keljo D, Moyer MS, Rufo PA, Wyllie R, Zachos M, Hyams J. Severe colitis in children. J Pediatr Gastroenterol Nutr 2005;41:375-85. [PMID: 16205502 DOI: 10.1097/01.mpg.0000186272.65559.ce] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 41 |
de Saussure P, Soravia C, Morel P, Hadengue A. Low-dose oral microemulsion ciclosporin for severe, refractory ulcerative colitis. Aliment Pharmacol Ther 2005;22:203-8. [PMID: 16091057 DOI: 10.1111/j.1365-2036.2005.02552.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 42 |
Message L, Bourreille A, Laharie D, Quinton A, Galmiche J, Lamouliatte H, Alamdari A, Zerbib F. Efficacy of intravenous cyclosporin in moderately severe ulcerative colitis refractory to steroids. Gastroentérologie Clinique et Biologique 2005;29:231-5. [DOI: 10.1016/s0399-8320(05)80754-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 43 |
Seksik P, Contou JF, Ducrotté P, Faucheron JL, de Parades V. [The treatment of distal ulcerative colitis]. Gastroenterol Clin Biol 2004;28:964-73. [PMID: 15672568 DOI: 10.1016/s0399-8320(04)95174-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 44 |
Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev. 2005;CD004277. [PMID: 15674937 DOI: 10.1002/14651858.cd004277.pub2] [Cited by in Crossref: 50] [Cited by in F6Publishing: 62] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 45 |
Bouhnik Y, Alvès A, Beau P, Carbonnel F, Lévy P. Traitement de la rectocolite ulcéro-hémorragique dans sa forme grave. Gastroentérologie Clinique et Biologique 2004;28:984-91. [DOI: 10.1016/s0399-8320(04)95176-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 46 |
Loftus CG, Egan LJ, Sandborn WJ. Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease. Gastroenterol Clin North Am 2004;33:141-69, vii. [PMID: 15177532 DOI: 10.1016/j.gtc.2004.02.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 47 |
Ho GT, Mowat C, Goddard CJ, Fennell JM, Shah NB, Prescott RJ, Satsangi J. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004;19:1079-87. [PMID: 15142197 DOI: 10.1111/j.1365-2036.2004.01945.x] [Cited by in Crossref: 186] [Cited by in F6Publishing: 131] [Article Influence: 9.8] [Reference Citation Analysis]
|
| 48 |
Moussata D, Nancey S, Flourié B, Bonvoisin SC, Cenni J, Descos L. Rectocolite ulcéro-hémorragique chronique active. La Presse Médicale 2004;33:590-4. [DOI: 10.1016/s0755-4982(04)98682-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 49 |
Arts J, D'Haens G, Zeegers M, Van Assche G, Hiele M, D'Hoore A, Penninckx F, Vermeire S, Rutgeerts P. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004;10:73-8. [PMID: 15168804 DOI: 10.1097/00054725-200403000-00002] [Cited by in Crossref: 176] [Cited by in F6Publishing: 145] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 50 |
Thuraisingam A, Leiper K. Medical management of ulcerative colitis. Hosp Med. 2003;64:703-707. [PMID: 14702780 DOI: 10.12968/hosp.2003.64.12.2360] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 51 |
Kamm MA. Antagonist: Early surgical intervention in ulcerative colitis. Gut 2004;53:308-9. [PMID: 14724169 DOI: 10.1136/gut.2003.001727] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 52 |
Fedorak RN. Conservative approach to severe ulcerative colitis. Dig Liver Dis 2004;36:4-6. [PMID: 14971809 DOI: 10.1016/j.dld.2003.10.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 53 |
Cheung O, Regueiro MD. Inflammatory bowel disease emergencies. Gastroenterol Clin North Am 2003;32:1269-88. [PMID: 14696307 DOI: 10.1016/s0889-8553(03)00095-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 54 |
Alves A, Panis Y, Bouhnik Y, Maylin V, Lavergne-Slove A, Valleur P. Subtotal colectomy for severe acute colitis: a 20-year experience of a tertiary care center with an aggressive and early surgical policy. J Am Coll Surg 2003;197:379-85. [PMID: 12946792 DOI: 10.1016/S1072-7515(03)00434-4] [Cited by in Crossref: 96] [Cited by in F6Publishing: 100] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 55 |
Rayner CK, McCormack G, Emmanuel AV, Kamm MA. Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis. Aliment Pharmacol Ther 2003;18:303-8. [PMID: 12895214 DOI: 10.1046/j.1365-2036.2003.01618.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 56 |
Creed TJ, Norman MR, Probert CS, Harvey RF, Shaw IS, Smithson J, Anderson J, Moorghen M, Gupta J, Shepherd NA, Dayan CM, Hearing SD. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003;18:65-75. [PMID: 12848627 DOI: 10.1046/j.1365-2036.2003.01639.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 95] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 57 |
Probert CS, Hearing SD, Schreiber S, Kühbacher T, Ghosh S, Arnott ID, Forbes A. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003;52:998-1002. [PMID: 12801957 DOI: 10.1136/gut.52.7.998] [Cited by in Crossref: 243] [Cited by in F6Publishing: 270] [Article Influence: 12.2] [Reference Citation Analysis]
|
| 58 |
Kornbluth A. Is there still a role for cyclosporine in the treatment of inflammatory bowel disease? Pro argument. Inflamm Bowel Dis 2003;9:194-7; discussion 202-4. [PMID: 12792226 DOI: 10.1097/00054725-200305000-00008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 59 |
Shibolet O, Regushevskaya E, Hershko A, Soares-weiser K, Brezis M. Cyclosporine A for induction of remission in steroid refractory ulcerative colitis. The Cochrane Database of Systematic Reviews 2003. [DOI: 10.1002/14651858.cd004277] [Reference Citation Analysis]
|
| 60 |
Tomomasa T, Kobayashi A, Kaneko H, Mika S, Maisawa S, Chino Y, Syou H, Yoden A, Fujino J, Tanikawa M, Yamashita T, Kimura S, Kanoh M, Sawada K, Morikawa A. Granulocyte adsorptive apheresis for pediatric patients with ulcerative colitis. Dig Dis Sci 2003;48:750-4. [PMID: 12741466 DOI: 10.1023/a:1022892927121] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 61 |
Dunckley P, Jewell D. Management of acute severe colitis. Best Pract Res Clin Gastroenterol 2003;17:89-103. [PMID: 12617885 DOI: 10.1053/bega.2002.0343] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 62 |
Lindsey I, Mcc Mortensen NJ. Surgical management of ulcerative colitis. Inflammatory Bowel Disease: From Bench to Bedside 2003. [DOI: 10.1007/978-1-4020-3477-0_31] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 63 |
Sandborn WJ. Medical management of ulcerative colitis. Inflammatory Bowel Disease: From Bench to Bedside 2003. [DOI: 10.1007/978-1-4020-3477-0_30] [Reference Citation Analysis]
|
| 64 |
Hanai H, Watanabe F, Takeuchi K, Iida T, Yamada M, Iwaoka Y, Saniabadi A, Matsushita I, Sato Y, Tozawa K, Arai H, Furuta T, Sugimoto K, Bjarnason I. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol 2003;1:28-35. [PMID: 15017514 DOI: 10.1053/jcgh.2003.50005] [Cited by in Crossref: 160] [Cited by in F6Publishing: 162] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 65 |
Fellermann K. Cyclosporin A und Tacrolimus. Chronisch entzündliche Darmerkrankungen 2003. [DOI: 10.1007/978-3-642-19025-4_10] [Reference Citation Analysis]
|
| 66 |
Escher JC, Taminiau JA, Nieuwenhuis EE, Büller HA, Grand RJ. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis 2003;9:34-58. [PMID: 12656136 DOI: 10.1097/00054725-200301000-00006] [Cited by in Crossref: 93] [Cited by in F6Publishing: 98] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 67 |
Hyde GM, Jewell DP, Warren BF. Histological changes associated with the use of intravenous cyclosporin in the treatment of severe ulcerative colitis may mimic dysplasia. Colorectal Dis 2002;4:455-8. [PMID: 12790919 DOI: 10.1046/j.1463-1318.2002.00392.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 46] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 68 |
Actis GC, Bruno M, Pinna-Pintor M, Rossini FP, Rizzetto M. Infliximab for treatment of steroid-refractory ulcerative colitis. Dig Liver Dis 2002;34:631-4. [PMID: 12405249 DOI: 10.1016/s1590-8658(02)80205-5] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 69 |
Simmons J, Jewell DP. Infliximab for ulcerative colitis. Dig Liver Dis 2002;34:616-8. [PMID: 12405245 DOI: 10.1016/s1590-8658(02)80201-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 70 |
Fellermann K, Tanko Z, Herrlinger KR, Witthoeft T, Homann N, Bruening A, Ludwig D, Stange EF. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002;8:317-24. [PMID: 12479646 DOI: 10.1097/00054725-200209000-00002] [Cited by in Crossref: 117] [Cited by in F6Publishing: 117] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 71 |
McCormack G, McCormick PA, Hyland JM, O'Donoghue DP. Cyclosporin therapy in severe ulcerative colitis: is it worth the effort? Dis Colon Rectum 2002;45:1200-5. [PMID: 12352237 DOI: 10.1007/s10350-004-6393-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 72 |
Kamm MA. Review article: maintenance of remission in ulcerative colitis. Aliment Pharmacol Ther 2002;16 Suppl 4:21-4. [PMID: 12047255 DOI: 10.1046/j.1365-2036.16.s4.4.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 73 |
Cunliffe RN, Scott BB. Review article: monitoring for drug side-effects in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:647-62. [PMID: 11929382 DOI: 10.1046/j.1365-2036.2002.01216.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 66] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 74 |
Banerjee S, Peppercorn MA. Inflammatory bowel disease. Medical therapy of specific clinical presentations. Gastroenterol Clin North Am 2002;31:185-202, x. [PMID: 12122731 DOI: 10.1016/s0889-8553(01)00012-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 75 |
Harrison J, Hanauer SB. Medical treatment of Crohn's disease. Gastroenterol Clin North Am 2002;31:167-84, x. [PMID: 12122730 DOI: 10.1016/s0889-8553(01)00011-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 76 |
Modigliani R. Medical management of fulminant colitis. Inflamm Bowel Dis 2002;8:129-34; discussion 138-9. [PMID: 11854611 DOI: 10.1097/00054725-200203000-00009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 77 |
Hyde GM, Jewell DP, Kettlewell MG, Mortensen NJ. Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications. Dis Colon Rectum 2001;44:1436-40. [PMID: 11598471 DOI: 10.1007/BF02234594] [Cited by in Crossref: 95] [Cited by in F6Publishing: 97] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 78 |
Fellermann K, Herrlinger K, Witthoeft T, Homann N, Ludwig D, Stange E. Tacrolimus: a new immunosuppressant for steroid refractory inflammatory bowel disease. Transplantation Proceedings 2001;33:2247-8. [DOI: 10.1016/s0041-1345(01)01979-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 79 |
Parkes M, Jewell DP. Review article: the management of severe Crohn's disease. Aliment Pharmacol Ther 2001;15:563-73. [PMID: 11328250 DOI: 10.1046/j.1365-2036.2001.00963.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 80 |
Witthöft T, Fellermann K. Einsatz neuer Immunsuppressiva. Chronisch entzündliche Darmerkrankungen 2001. [DOI: 10.1007/978-3-642-59556-1_12] [Reference Citation Analysis]
|
| 81 |
Treiber G. Mycophenolate mofetil for therapy-resistant interstitial lung disease associated with ulcerative colitis. Am J Gastroenterol 2000;95:3674-5. [PMID: 11151935 DOI: 10.1111/j.1572-0241.2000.03415.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 82 |
Blomberg B, Järnerot G. Clinical evaluation and management of acute severe colitis. Inflamm Bowel Dis 2000;6:214-27. [PMID: 10961594 DOI: 10.1097/00054725-200008000-00008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 83 |
Rowe FA, Walker JH, Karp LC, Vasiliauskas EA, Plevy SE, Targan SR. Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis. Am J Gastroenterol 2000;95:2000-8. [PMID: 10950049 DOI: 10.1111/j.1572-0241.2000.02186.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 84 |
Wong CK, Yacyshyn BR. Fulminant Ulcerative Colitis. Curr Treat Options Gastroenterol 2000;3:217-26. [PMID: 11097739 DOI: 10.1007/s11938-000-0025-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 85 |
Orth T, Peters M, Schlaak JF, Krummenauer F, Wanitschke R, Mayet WJ, Galle PR, Neurath MF. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol 2000;95:1201-7. [PMID: 10811328 DOI: 10.1111/j.1572-0241.2000.02010.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 86 |
Kornbluth A. Cyclosporine in inflammatory bowel disease. Curr Gastroenterol Rep 1999;1:486-90. [PMID: 10980991 DOI: 10.1007/s11894-999-0008-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 87 |
Belaiche J. Traitement médical des colites inflammatoires aiguës graves. Acta Endosc 1999;29:569-575. [DOI: 10.1007/bf03022169] [Reference Citation Analysis]
|
| 88 |
Ooi CJ, Sands BE. Treatment of ulcerative colitis. Curr Opin Gastroenterol 1999;15:298-301. [PMID: 17023961 DOI: 10.1097/00001574-199907000-00004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
|
